S
Stockadora
Back to Insider Trading View Full Company Profile

TVTX

HEALTHY

Travere Therapeutics, Inc.

CIK: 0001438533

Strong Sell (90% confidence)

Last activity: 1 weeks ago

Financial Metrics

As of Dec 31, 2024 (10-K)

Net Income -$321.55M
Current Ratio 2.08

Insider Roster (7 total, 7 active)

Insider Buys Sells Net Value Holdings
Dube Eric M
CHIEF EXECUTIVE OFFICER
 		0 4 -$5.04M
466,521 shares
$14.96M
ROTE WILLIAM E.
Chief Research Officer
 		0 2 -$2.82M
109,087 shares
$3.59M
Inrig Jula
CHIEF MEDICAL OFFICER
 		0 6 -$1.01M
105,938 shares
$3.40M
Cline Christopher R.
CHIEF FINANCIAL OFFICER
 		0 4 -$989K
111,336 shares
$3.58M
REED ELIZABETH E
Chief Legal Officer and GC
 		0 4 -$600K
105,720 shares
$3.39M
Calvin Sandra
SVP, CHIEF ACCOUNTING OFFICER
 		0 3 -$540K
49,080 shares
$1.58M
Heerma Peter
CHIEF COMMERCIAL OFFICER
 		0 2 -$434K
131,823 shares
$4.23M

Recent Transactions

SELL REED ELIZABETH E (Chief Legal Officer and GC)

2,485 shares @ $32.07

$80K

Feb 4, 2026

Conviction: | View SEC Filing →
SELL Cline Christopher R. (CHIEF FINANCIAL OFFICER)

1,635 shares @ $32.14

$53K

Feb 4, 2026

Conviction: | View SEC Filing →
SELL Inrig Jula (CHIEF MEDICAL OFFICER)

1,547 shares @ $32.11

$50K

Feb 4, 2026

Conviction: | View SEC Filing →
SELL REED ELIZABETH E (Chief Legal Officer and GC)

509 shares @ $32.74

$17K

Feb 4, 2026

Conviction: | View SEC Filing →
SELL Inrig Jula (CHIEF MEDICAL OFFICER)

232 shares @ $32.85

$8K

Feb 4, 2026

Conviction: | View SEC Filing →
SELL Cline Christopher R. (CHIEF FINANCIAL OFFICER)

110 shares @ $32.90

$4K

Feb 4, 2026

Conviction: | View SEC Filing →
SELL Dube Eric M (CHIEF EXECUTIVE OFFICER)

66,452 shares @ $32.06

$2.13M

Feb 3, 2026

Conviction: | View SEC Filing →
SELL Dube Eric M (CHIEF EXECUTIVE OFFICER)

33,635 shares @ $32.70

$1.10M

Feb 3, 2026

Conviction: | View SEC Filing →
SELL ROTE WILLIAM E. (Chief Research Officer)

12,446 shares @ $32.87

$409K

Feb 3, 2026

Conviction: | View SEC Filing →
SELL Heerma Peter (CHIEF COMMERCIAL OFFICER)

7,310 shares @ $32.12

$235K

Feb 3, 2026

Conviction: | View SEC Filing →
SELL Cline Christopher R. (CHIEF FINANCIAL OFFICER)

7,242 shares @ $32.12

$233K

Feb 3, 2026

Conviction: | View SEC Filing →
SELL REED ELIZABETH E (Chief Legal Officer and GC)

7,175 shares @ $32.12

$230K

Feb 3, 2026

Conviction: | View SEC Filing →
SELL Inrig Jula (CHIEF MEDICAL OFFICER)

6,956 shares @ $32.12

$223K

Feb 3, 2026

Conviction: | View SEC Filing →
SELL Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER)

4,333 shares @ $32.12

$139K

Feb 3, 2026

Conviction: | View SEC Filing →
SELL Dube Eric M (CHIEF EXECUTIVE OFFICER)

51,865 shares @ $30.10

$1.56M

Jan 27, 2026

Conviction: | View SEC Filing →
SELL Dube Eric M (CHIEF EXECUTIVE OFFICER)

8,135 shares @ $30.01

$244K

Jan 23, 2026

Conviction: | View SEC Filing →
SELL REED ELIZABETH E (Chief Legal Officer and GC)

10,000 shares @ $27.34

$273K

Jan 20, 2026

Conviction: | View SEC Filing →
SELL Inrig Jula (CHIEF MEDICAL OFFICER)

445 shares @ $37.75

$17K

Jan 6, 2026

Conviction: | View SEC Filing →
SELL Inrig Jula (CHIEF MEDICAL OFFICER)

2,031 shares @ $40.18

$82K

Jan 5, 2026

Conviction: | View SEC Filing →
SELL ROTE WILLIAM E. (Chief Research Officer)

60,000 shares @ $40.10

$2.41M

Dec 24, 2025

Conviction: | View SEC Filing →
SELL Inrig Jula (CHIEF MEDICAL OFFICER)

15,000 shares @ $42.00

$630K

Dec 24, 2025

Conviction: | View SEC Filing →
SELL Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER)

7,402 shares @ $40.00

$296K

Dec 24, 2025

Conviction: | View SEC Filing →
SELL Heerma Peter (CHIEF COMMERCIAL OFFICER)

4,980 shares @ $40.00

$199K

Dec 24, 2025

Conviction: | View SEC Filing →
SELL Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER)

2,910 shares @ $36.00

$105K

Dec 15, 2025

Conviction: | View SEC Filing →
SELL Cline Christopher R. (CHIEF FINANCIAL OFFICER)

20,000 shares @ $35.01

$700K

Dec 1, 2025

Conviction: | View SEC Filing →

⚠️ Important Disclaimer

• This is AI-generated analysis for educational purposes only, not financial advice.

• Insider trading data is derived from SEC Form 4 filings and may contain errors.

• Always conduct your own research and consult qualified financial advisors before making investment decisions.